CAJ | 학술논문

目的：探讨安神胶囊对慢性精神分裂症患者认知和社会功能的影响。方法：采用随机、双盲、双模拟试验方法，将200例患者随机分为观察组和对照组各100例，观察组口服安神胶囊，4粒/次，3次/d；对照组口服维思通，1～1.5 mg/d，2组均治疗8周。于基线和治疗8周末分别计算认知功能评定量表（WCST）评分、社会功能量表（SDSS)评分；于治疗前，治疗第2、4、6、8周分别计算阳性症状量表（SAPS）评分、阴性症状量表（SANS）评分、临床总体印象量表（CGI）评分，并以药物副反应量表（TESS)评定药物的副反应。结果：治疗第8周末，2组SAPS、SANS及SDSS评分均较基线降低，WCST指标中除了观察组持续应答数外均获改善，差异均有统计学意义（P＜0.05）；观察组SANS、SAPS评分的降低较对照组更为明显（P＜0.05)。安神胶囊组WCST各指标改善较对照组明显（P＜0.05)。 SANA有效率、CGI临床进步率观察组分别为79.9%、86.6%，对照组分别为85.3%、89.3%,2组比较差异均无统计学意义（P＞0.05)。结论：安神胶囊对慢性精神分裂症患者认知和社会功能的改善更为有效，且副反应小。
목적：탐토안신효낭대만성정신분렬증환자인지화사회공능적영향。방법：채용수궤、쌍맹、쌍모의시험방법，장200례환자수궤분위관찰조화대조조각100례，관찰조구복안신효낭，4립/차，3차/d；대조조구복유사통，1～1.5 mg/d，2조균치료8주。우기선화치료8주말분별계산인지공능평정량표（WCST）평분、사회공능량표（SDSS)평분；우치료전，치료제2、4、6、8주분별계산양성증상량표（SAPS）평분、음성증상량표（SANS）평분、림상총체인상량표（CGI）평분，병이약물부반응량표（TESS)평정약물적부반응。결과：치료제8주말，2조SAPS、SANS급SDSS평분균교기선강저，WCST지표중제료관찰조지속응답수외균획개선，차이균유통계학의의（P＜0.05）；관찰조SANS、SAPS평분적강저교대조조경위명현（P＜0.05)。안신효낭조WCST각지표개선교대조조명현（P＜0.05)。 SANA유효솔、CGI림상진보솔관찰조분별위79.9%、86.6%，대조조분별위85.3%、89.3%,2조비교차이균무통계학의의（P＞0.05)。결론：안신효낭대만성정신분렬증환자인지화사회공능적개선경위유효，차부반응소。
To explore the effects ofAnshencapsule on cognitive and social function of cases with chronic schizophrenia. Methods: All 200 cases were divided into the observation group and the control group, with 100 cases in each. The observation group was treated by orally takingAnShencapsule, with four pills per time and three times per day, and the control group were given risperidone (1~1.5 mg/d). Treatment last for eight weeks in two groups. Scores of WCST and SDSS were calculated from the baseline and the end of 8 th week after treatment; scores of SAPS, SANS, CGI and TESS WERE calculated before the treatment and at 2 th, 4 th, 6 th and 8 th week during treatment. Results: At the end of 8th week, scores of SAPS, SANS and SDSS in two groups decreased when compared to that of the baseline. All indicators in WCST got improvement except constant answering, which indi-cated that there was statistical significance (P<0.05). And the decrease of scores of SANS and SAPS were much more obvious when compared to that of the control group. Compared to the control group, indicators ofAnshencap-sule group got better improvement(P<0.05). Efficiency of SANA and of CGI were 79.9%, 86.6% and 85.3%, 89.3% respectively, which showed no statistical significance between two groups (P>0.05). Conclusion:Anshencapsule is effective in improving cognitive and social function of patients with chronic schizophrenia and has little side effects.